More recently, there has been a renewed interest regarding the interaction between ER+ breast cancer and immune system/inflammatory response, probably on the wave of the relevant goals achieved in treatment of other malignancies including metastatic lung cancer, melanoma and TNBC [57,58,59]. This evidence concerns the gene ESR1 and breast carcinoma.